Last reviewed · How we verify

Genprex, Inc. — Portfolio Competitive Intelligence Brief

Genprex, Inc. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Platinum-Based Chemotherapy Platinum-Based Chemotherapy marketed Platinum-based alkylating agent DNA Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bristol-Myers Squibb · 1 shared drug class
  2. Cedars-Sinai Medical Center · 1 shared drug class
  3. Insel Gruppe AG, University Hospital Bern · 1 shared drug class
  4. Ming-Yuan Chen · 1 shared drug class
  5. Peking University Third Hospital · 1 shared drug class
  6. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 shared drug class
  7. Sun Yat-sen University · 1 shared drug class
  8. Tata Memorial Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Genprex, Inc.:

Cite this brief

Drug Landscape (2026). Genprex, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/genprex-inc. Accessed 2026-05-14.

Related